Cost pressure of the new hepatitis C drugs in Canada = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.: H82-25/2016-PDF
"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments."
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.833934&sl=0
| Department/Agency | Canada. Patented Medicine Prices Review Board. National Prescription Drug Utilization Information System (Canada) |
|---|---|
| Title | Cost pressure of the new hepatitis C drugs in Canada = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada. |
| Variant title | Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada |
| Publication type | Monograph |
| Language | Bilingual-[English | French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Caption title. At head of title: National Prescription Drug Utilization Information System. Text in English and French. |
| Publishing information | [Ottawa] : Patented Medicine Prices Review Board, [2016] |
| Description | [1] p. : col. charts |
| Catalogue number |
|
| Subject terms | Hepatitis Drugs Prices |